Cesar

Director of Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists, Lake Nona @SarahCannonDocs #hncsm #HeadandNeckCancer

[CancerNetwork® @CancerNetwrk]

The FDA has granted FTD to CRB-701, a next-generation ADC targeting nectin-4, for patients with recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy and an anti-PD(L)1 therapy.

https://t.co/psrUYgFUBE

#hncsm #oncology #cancer

[Sarah Cannon Docs @SarahCannonDocs]

Dr. Cesar Perez presenting at the educational session on Head and neck cancers at ASCO 2024 #ASCO24

[ESMO - Eur. Oncology @myESMO]

Recommendations for Global Curriculum in #MedicalOncology: result of great collaboration btw @myesmo & @ASCO and the full support of @JCOGO_ASCO & @ESMO_Open

[Dr. Estela Rodriguez @Latinamd]

Si la montaña no va a Mahoma, Mahoma va a la montaña. ( If the mountain does not come to Mohammed…)

Visiting our former @SylvesterCancer colleague and friend @CesarAPerezMD in Lake Nona, FL. @FLCancerFound

[Cesar @CesarAPerezMD]

@Latinamd @SylvesterCancer @FLCancerFound 😁 Awesome to see you my friend!

[Cesar @CesarAPerezMD]

@VivekSubbiah @ErikaHamilton9 @jacobadashek @neerajaiims @BldCancerDoc @OncHahn @doctorpemm @BurrisSkip @jeffyoriomd @weldeiry You guys are the best of the best!

[gilberto lopes @GlopesMd]

@CesarAPerezMD @m_mutebi @asco #asco23

[Cesar @CesarAPerezMD]

@VivekSubbiah @SarahCannonDocs Welcome @VivekSubbiah! We are thrilled! @SarahCannonDocs

[OncLive.com @OncLive]

.@US_FDA granted a fast track designation to KIN-2787 in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma. @CesarAPerezMD @SarahCannonDocs #melcsm
https://t.co/9fY9F1HWdR

[Cesar @CesarAPerezMD]

@GlopesMd @Starasvetska_MD Congrats Guys! 🥳

[Sarah Cannon Docs @SarahCannonDocs]

It's World Cancer Research Day and Dr. Cesar Perez, Director of Drug Development at Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, is sharing his wisdom on the importance of clinical trials in the life of patients facing cancer. #WorldCancerResearchDay

[NatureRevClinOncol @NatRevClinOncol]

In the phase III JUPITER-02 trial, addition of the anti-PD-1 antibody toripalimab to first-line gemcitabine plus cisplatin for pts with advanced-stage nasopharyngeal carcinoma improved PFS 11.7 vs 8.2 months and also OS (HR 0.61, P = 0.046): https://t.co/wcKcPRGPbP #hncsm

[Cesar @CesarAPerezMD]

@GlopesMd It’s quite a sad story, how a scientifically proven solution is not yet embraced universally. Numbers are quite clear in Miami-Dade county: Of all the patients hospitalized, >96% are UN-vaccinated or immunosuppressed.

[OncLive.com @OncLive]

According to data from a landmark phase 3 trial, in the ITT population of patients with advanced primary SCCHN, the Multikine treatment regimen yielded an OS benefit of 14.1%. #hncsm https://t.co/9zP9BYV97q

[Cesar @CesarAPerezMD]

@GlopesMd @SylvesterCancer Best of Luck to the new HemOnc Fellows! @SylvesterCancer

[Ezra Cohen @DrEzraCohen]

Cabozantinib demonstrates efficacy in radioactive-iodine and VEGFR refractory patients. Another option for thyroid cancer patients but keep in mind the importance of molecular testing to find actionable alterations in NTRK, RET, and BRAF.
https://t.co/LAgPy5084w

[ASCO @ASCO]

#ASCO21 Press Release: JUPITER-02 Trial- Toripalimab plus standard first-line chemo significantly delayed disease progression for pts w recurrent or metastatic nasopharyngeal carcinoma https://t.co/Wdfi9TI1t0 #hncsm #immunoonc